Need more information?
We Offer You…
» Online support by email or telephone 24×7
» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems
» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.
» A Minimum Content Delivery initiation time of 9 hours
» An opportunity to be considered as an Expert Panel Member
» The provision of live, domain-specific updates
Myelodysplastic Syndromes: Comprehensive Global Clinical Trials Analytics H2 2018
- 145 Pages | Published On: 03-Apr-18 | Format:PDF | Last Updated: Updation in process
-
“GervanoRA’s Clinical trials report “Myelodysplastic Syndromes: Comprehensive Global Clinical Trials Analytics H2 2018” provides an in-depth analysis of the overall clinical trials for Myelodysplastic Syndromes. The report caters information related to the global clinical trials with respect to their Phase, Trial Status, Intervention, Trial type and Endpoint status. Our report exclusively focuses on providing insights and competitive opportunities based on Biomarker or target receptor, Drug Class and Mechanism of Action to aid in understanding the upcoming newer research trends in the field of Myelodysplastic Syndromes drug discovery. The report offers coverage of Myelodysplastic Syndromes clinical trials by region and average enrollment by country. Country based analytics are provided according to the Top 5 Clinical trial sites globally and the emerging countries supporting with a platform to conduct clinical trials effectively. Analytics are also provided for the subjects enrolled over a period of time, Myelodysplastic Syndromes clinical trials by sponsor type and the top companies involved in the R&D of Myelodysplastic Syndromes drug development. In addition, the report gives a brief overview on the major drugs undergoing trials and the recent advancements observed in the Myelodysplastic Syndromes clinical trials.
-
TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. GERVANORA CLINICAL TRIALS REPORT COVERAGE
3. EXECUTIVE SUMMARY
3.1 MAJOR FINDINGS
3.2 TRIALS EXPECTED TO COMPLETE IN 5 YEARS
4. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
5. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
6. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
7. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY PHASE
7.1 ONGOING CLINICAL TRIALS BY PHASE
7.2 COMPLETED CLINICAL TRIALS BY PHASE
7.3 UPCOMING CLINICAL TRIALS BY PHASE (NOT YET RECRUITING)
8. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY REGION
9. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TRIAL STATUS (INCLUDING EXPANDED ACCESS)
10. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY INTERVENTION
11. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TYPE
12. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY ENDPOINT STATUS
13. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
13.1 ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
13.1.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN THE US
13.1.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN GERMANY
13.1.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN JAPAN
13.1.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN FRANCE
13.1.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN SPAIN
13.2 ANALYTICS BY EMERGING CLINICAL TRIAL SITES
13.2.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHINA
13.2.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN INDIA
13.2.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN RUSSIA
13.2.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AUSTRALIA
13.2.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN BRAZIL
13.2.6 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHILE
13.2.7 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AFRICA
13.2.8 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN MIDDLE EAST
14. SUBJECTS RECRUITED OVER A PERIOD OF TIME
15. MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY SPONSOR TYPE
15.1. TOP COMPANIES PARTICIPATING IN MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS
16. MAJOR DRUGS UNDERGOING TRIALS
17. RECENT ADVANCEMENTS IN MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS
18. ABBREVIATIONS
LIST OF TABLES:
TABLE 01: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS TO BE COMPLETED IN 5 YEARS
TABLE 02: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS
TABLE 03: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
TABLE 04: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
TABLE 05: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
TABLE 06: DRUG CLASS BASED MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS
TABLE 07: DRUG CLASS BASED MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 1
TABLE 08: DRUG CLASS BASED MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 2
TABLE 09: DRUG CLASS BASED MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 3
TABLE 10: MECHANISM OF ACTION BASED MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS
TABLE 11: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BASED ON HSD
TABLE 12: ONGOING CLINICAL TRIALS ANALYTICS BY HSD
TABLE 13: COMPLETED CLINICAL TRIALS ANALYTICS BY HSD
TABLE 14: UPCOMING CLINICAL TRIALS ANALYTICS BY HSD
TABLE 15: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY REGION
TABLE 16: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TRIAL STATUS
TABLE 17: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TYPE
TABLE 18: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, TOP 5 CLINICAL TRIAL SITES
TABLE 19: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN THE US, PHASE AND TRIAL STATUS
TABLE 20: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN GERMANY, PHASE AND TRIAL STATUS
TABLE 21: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN JAPAN, PHASE AND TRIAL STATUS
TABLE 22: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN FRANCE, PHASE AND TRIAL STATUS
TABLE 23: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN SPAIN, PHASE AND TRIAL STATUS
TABLE 24: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, EMERGING CLINICAL TRIAL SITES
TABLE 25: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN CHINA, PHASE AND TRIAL STATUS
TABLE 26: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN INDIA, PHASE AND TRIAL STATUS
TABLE 27: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN RUSSIA, PHASE AND TRIAL STATUS
TABLE 28: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN AUSTRALIA, PHASE AND TRIAL STATUS
TABLE 29: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN BRAZIL, PHASE AND TRIAL STATUS
TABLE 30: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN CHILE, PHASE AND TRIAL STATUS
TABLE 31: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN AFRICA, PHASE AND TRIAL STATUS
TABLE 32: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS IN MIDDLE EAST, PHASE AND TRIAL STATUS
TABLE 33: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY SPONSOR TYPE
TABLE 34: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS, TOP COMPANIES
TABLE 35: ANALYTICS OF THE MAJOR DRUGS BY HIGHEST STAGE OF DEVELOPMENT
LIST OF FIGURES:
FIGURE 01: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS, BIOMARKERS OR TARGET RECEPTOR BASED SCENARIO
FIGURE 02: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 3 CLINICAL TRIALS ANALYTICS
FIGURE 03: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 2 CLINICAL TRIALS ANALYTICS
FIGURE 04: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 1 CLINICAL TRIALS ANALYTICS
FIGURE 05: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BY DRUG CLASS
FIGURE 06: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
FIGURE 07: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
FIGURE 08: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
FIGURE 09: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS ANALYTICS BY MECHANISM OF ACTION
FIGURE 10: CLINICAL TRIAL ANALYTICS, HSD SPLIT-UP
FIGURE 11: ONGOING CLINICAL TRIALS BY PHASE
FIGURE 12: COMPLETED CLINICAL TRIALS BY PHASE
FIGURE 13: UPCOMING CLINICAL TRIALS BY PHASE
FIGURE 14: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY REGION
FIGURE 15: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TRIAL STATUS
FIGURE 16: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY TYPE
FIGURE 17: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS BY ENDPOINT STATUS
FIGURE 18: MYELODYSPLASTIC SYNDROMES CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
FIGURE 19: CLINICAL TRIAL ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
FIGURE 20: CLINICAL TRIAL ANALYTICS BY EMERGING CLINICAL TRIAL SITES
FIGURE 21: MYELODYSPLASTIC SYNDROMES CLINICAL TRIAL ANALYTICS, SPLIT BY SPONSOR TYPE
